Why insider trading matters?

Numerous studies have examined whether there is evidence that U.S. insiders systematically trade on private information despite the legal deterrence. The consensus appears to be that insider purchases (but not sales) tend to be followed by positive abnormal stock price performance, particularly for small growth stocks.

- Prof. B. Espen Eckbo, Dartmouth College
Tracon Pharmaceuticals, Inc. (TCON)
Sector: Healthcare; Industry: Biotechnology

TRACON Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for cancer and wet age-related macular degeneration (AMD). The company also develops TRC102, a small molecule that is in Phase II clinical trial for mesothelioma, Phase I clinical trial for solid tumors and lung cancer, and Phase I/II clinical trial for solid tumors and lymphomas; and TRC253, a small molecule high affinity competitive inhibitor of wild type androgen receptor (AR) and multiple AR mutant receptors that is in Phase I/II clinical trial for the treatment prostate cancer. The company has license agreements with Ambrx, Inc.; Santen Pharmaceutical Co. Ltd.; Roswell Park Cancer Institute and Health Research Inc.; Case Western Cancer Center; and Lonza Sales AG, as well as a cooperative research and development agreement with National Cancer Institute. TRACON Pharmaceuticals, Inc. was founded in 2004 and is headquartered in San Diego, California.


Trade Date Insider Title Buy/Sell #Shares Price Value Option
2018-03-27 Florence Anthony A. Jr. 10%-Owner Buy 707,964 $2.70 $1,911,503 Yes
2016-11-29 Florence Anthony A. Jr. 10%-Owner Buy 869,565 $5.75 $4,999,999 No
2015-02-04 Florence Anthony A. Jr. 10%-Owner Buy 500,000 $10.00 $5,000,000 Yes

Insider Smart

Liberty Media Corp (LSXMA) - BERKSHIRE HATHAWAY INC, Buffett made a move and add 2M shares to their position. What a news after dumping Airlines.

Insider Smart

SIMON PROPERTY GROUP (SPG) - Bottom fishing the crash could be intimidating, but it can be easier if you know insiders are on your side. Aeppel Glyn, Director of SPG played safe and bought shares in May at $50, but it is not late at all, the stock is now $90.